Cancer Research UK on Google+ Cancer Research UK on Facebook Cancer Research UK on Twitter
 

Browse by research type

Use the links below to jump to lists of funding schemes by research type.

Cancer Research UK does not fund research into palliative/end of life care, psychosocial oncology (including survivorship and quality of life issues), or health services research.

For further details of the research areas that Cancer Research UK funds and will continue to fund, see our research strategy.

 

Behavioural prevention research

Cancer Research UK supports educational and behavioural research in the areas of prevention, screening and early diagnosis. Our research in this area includes projects on smoking cessation.

 

Biomarker studies

Cancer Research UK supports research on biomarker discovery, development and qualification. Our research in this area includes projects on predisposition, screening, diagnostic, prognostic, predictive and surrogate response biomarkers.

 

Cancer imaging

Cancer Research UK supports research into the discovery and evaluation of imaging technology, including imaging biomarker studies and the development of imaging agents. Our research in this area includes preclinical but also clinical research projects testing new imaging agents in patients.

 

Cell and molecular biology

Cancer Research UK supports a wide range of biological science disciplines including cell biology, molecular biology and biochemistry, where these disciplines are applied to increase our understanding of cancer.

 

Confirmatory medicine clinical trials

Cancer Research UK supports large Phase II and Phase III cancer clinical trials that have the aim of testing cancer treatments such as chemotherapy, radiotherapy and surgery. Our trials look for outcomes such as disease progression, survival and mortality, as well as assessing toxicity, late effects of treatment and quality of life.

 

Drug discovery and development

Cancer Research UK supports research into the early development of innovative new cancer medicines with the aim of providing more treatment options for cancer patients. Our research in this area includes projects on molecularly targeted small molecules, cytotoxic agents, antibodies, vaccines, viral gene therapy, immunotherapy, cell therapy, diagnostic and imaging agents.

 

Exploratory medicine clinical trials

Cancer Research UK supports Phase I and Phase II cancer clinical trials with new anti-cancer agents, such as molecularly targeted small molecules, cytotoxic agents, antibodies, vaccines, viral gene therapy, immunotherapy, cell therapy, radioimmunotherapy, diagnostics and imaging agents. We also support trials that test aspects of the feasibility of larger-scale trials, or the tolerability or efficacy of new treatments.

 

Genetics and genetic epidemiology

Cancer Research UK supports research into cancer genetics, genomics and genetic epidemiology. Our research in this area aims to increase our understanding of the causes of cancer, and includes projects on cancer susceptibility genes and familial cancer syndromes.

 

Immunology and tumour biology

Cancer Research UK supports research in a wide range of disciplines that increase our understanding of the biology of tumours. Our research in this area includes projects in immunology, physiology and pathology.

 

Cancer prevention

Cancer Research UK supports research into all aspects of cancer prevention, including research into the awareness and early detection of cancer. We support research into the behavioural aspects of cancer prevention, as well as research on chemoprevention.

 

Public health epidemiology

Cancer Research UK supports research into clinical and public health epidemiology in cancer. Our research in this area aims to increase our understanding of the factors that cause cancer. The research includes projects on clinical trials methodologies and statistics.

 

Tobacco control policy and advocacy

Cancer Research UK supports research in tobacco control policy and advocacy, as well as into health promotion and health interventions. This research complements our policy and campaigning work in these areas.

 

Updated: 12 December 2011